CA-TIGO
23.9.2019 17:38:07 CEST | Business Wire | Press release
Tigo® , pioneer of the smart modular Flex MLPE & TS4 Platform, today announced its new TS4-A-2F (Fire Safety) , the advanced retrofit/add-on rapid shutdown solution for two modules that provides smart PV module functionality. The TS4-A-2F is the newest, most partner adopted, and most cost-effective addition to Tigo’s advanced generation of flexible module-level power electronics in the TS4 Platform .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005637/en/
The UL-certified TS4-A-2F complies with NEC 2017 690.12 Rapid Shutdown specifications when installed with Tigo’s UL-certified RSS Transmitter or an inverter with Tigo's built-in RSS Transmitter. The unit’s powerline communication can be easily verified with Tigo’s RSS Signal Detector . System owners can ensure safety by upgrading existing PV systems or by adding these safety features to new installations. With this improved lightweight hardware, lower labor costs, and application for two modules, the TS4-A-2F is quickly becoming the most adopted rapid shutdown solution in the industry.
The highlights of TS4-A-2F include:
- Maximum Total Power is 1000W for two modules
- Maximum Current is 15A per input
- Available as 1500V UL
- UL-certified as NEC 2017 Rapid Shutdown Solution
- Snap to standard module frame or rack mounting
- Module-level deactivation with automatic or manual shutdown
- PV array enters rapid shutdown in event of AC grid loss
- Powerline communication (PLC) signaling
- Smaller unit dimensions with reduced weight per unit by 25%
- Reduced shipping costs with 33% more units per pallet
- Recessed mounting allows shipments of pre-assembled PV modules
- Improved heat dissipation with over-temperature and over-voltage protection
- Improved IP68 rating for greater outdoor exposure
- Download the datasheet here
Tigo’s TS4-A-2F will showcase at the Solar Power International (SPI) Exhibition Hall in Salt Lake City, Utah September 24 – 26, 2019. The UL-listed inverters with Tigo’s rapid shutdown solution showing at SPI include CPS (Booth 2201), Fronius (Booth 2019), GoodWe (Booth 2609), SolaX Power (Booth 719), Yaskawa Solectria Solar (Booth 2125), and more. The smart module manufacturers integrated with Tigo showing at SPI include GCL (Booth 1001), JA Solar (Booth 1219), Phono Solar (Booth 301), Suntech (Booth 211), Vikram Solar (4055), and more. To schedule an appointment or for an introduction to one of Tigo's manufacturing partners at SPI, contact sales@tigoenergy.com .
“Tigo’s TS4-A-2F is the most cost-effective rapid shutdown solution on the market today thanks to the accommodation of two modules,” says Zvi Alon, Chairman & CEO at Tigo. “Our inverter and module manufacturing partners see the value in this solution due to its readiness for new or existing systems of any size. Solar Power International is the perfect event to launch while we can collaborate with our many tier one partners to offer this UL-certified solution.”
Tigo’s TS4-A-2F is shipping with module manufacturers and distributors worldwide. This unit joins the other advanced retrofit/add-on units announced earlier this year: TS4-A-F (Fire Safety) , TS4-A-O (Optimization) , and TS4-A-O-Duo (Optimization per 2 modules) . For price and delivery, consult your preferred PV module supplier , call Tigo at +1.408.402.0802 ext. 1, or email sales@tigoenergy.com .
About Tigo
Tigo is a Silicon Valley company founded in 2007 by a team of experienced technologists. Combining a unique systems-level approach with expertise in semiconductors, power electronics, and solar energy, the Tigo team developed the first-generation Smart Module Optimizer technology for the solar industry. Tigo's vision is to leverage integrated and retrofitted Flex MLPE and communications technology to drive the cost of solar electricity down. By partnering with tier 1 module and inverter manufacturers in the industry, Tigo is able to focus on its key innovation with the smartest TS4 modular platform and leverage the broader ecosystem. Tigo has operations in the USA, Europe, Latin America, Japan, China, Australia, and the Middle East. Visit www.tigoenergy.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005637/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom